These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 9174388)
1. Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results. Gruss JD Vasa; 1997 May; 26(2):117-21. PubMed ID: 9174388 [TBL] [Abstract][Full Text] [Related]
2. [Combination of profundaplasty and pharmacotherapy in stage III/IV peripheral arterial occlusive disease]. Gruss JD Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1252-5. PubMed ID: 9931851 [TBL] [Abstract][Full Text] [Related]
3. Combined stent placement and high dose PGE1 drip infusion for chronic occlusion of the superficial femoral artery as a modality to salvage chronic critical limb ischemia. Ikushima I; Hirai T; Ishii A; Yamashita Y Eur J Radiol; 2008 Apr; 66(1):95-9. PubMed ID: 17555902 [TBL] [Abstract][Full Text] [Related]
4. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities]. Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749 [TBL] [Abstract][Full Text] [Related]
5. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation. Claeys LG; Horsch S Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776 [TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Creutzig A; Lehmacher W; Elze M Vasa; 2004 Aug; 33(3):137-44. PubMed ID: 15461065 [TBL] [Abstract][Full Text] [Related]
8. [Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease--is quantification of the therapeutic effect possible with tcPO2 measurements?]. Breuer C; Abri O Vasa; 1995; 24(1):62-71. PubMed ID: 7536999 [TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial. Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064 [TBL] [Abstract][Full Text] [Related]
10. Are there predictors for the outcome of a PGE1 treatment in peripheral arterial disease with critical limb ischaemia? Heidrich H; Schmidt T; Fahrig C Vasa; 2005 May; 34(2):101-7. PubMed ID: 15968891 [TBL] [Abstract][Full Text] [Related]
11. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. Brass EP; Anthony R; Dormandy J; Hiatt WR; Jiao J; Nakanishi A; McNamara T; Nehler M; J Vasc Surg; 2006 Apr; 43(4):752-9. PubMed ID: 16616232 [TBL] [Abstract][Full Text] [Related]
12. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148 [TBL] [Abstract][Full Text] [Related]
13. [Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study]. Trübestein G; Ludwig M; Diehm C; Gruss JD; Horsch S Dtsch Med Wochenschr; 1987 Jun; 112(24):955-9. PubMed ID: 3297596 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV. Balzer K; Rogatti W; Rüttgerodt K Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242 [TBL] [Abstract][Full Text] [Related]
15. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value. Creutzig A; Arnold A; Caspary L; Thum J; Alexander K Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319 [TBL] [Abstract][Full Text] [Related]
16. Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration. Serra W; Musiari L; Ardissino D; Gherli T; Montanari A Int J Cardiol; 2011 Jan; 146(1):e10-5. PubMed ID: 19176262 [TBL] [Abstract][Full Text] [Related]
17. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy. Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444 [TBL] [Abstract][Full Text] [Related]
18. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953 [TBL] [Abstract][Full Text] [Related]
19. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases]. Bucci M; Iacobitti P; Laurora G; Cesarone MR Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439 [TBL] [Abstract][Full Text] [Related]
20. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease]. Hesse WH; Rudofsky G; Peskar BA Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]